The Effects and Symptoms of Long COVID-19
An outpatient care coordinator discusses the systemic and psychiatric symptoms of COVID-19 long haulers, as well as differences in outcomes based on vaccination.
Launching a Long Haul COVID-19 Clinic
A look into how Allegheny Health Network launched its multi-specialty referral system for post-hospitalized COVID-19 patients.
Why Sickle Cell Drug Options Are Underwhelming
Findings from the SWAY trial highlight a pressing need for varying and more personalized treatment methods for patients.
Emerging Treatments in C Difficile
Dr. Carl V. Crawford led a panel in discussing treatments in the pipeline for CDI.
ARU-1801 Yields Promise for Severe Sickle Cell Disease in Phase 1/2 Trial
New ASH 2021 data for the stem cell transplant therapy suggest it has a durable and safe benefit for adults with severe disease.
Global SWAY Survey Shows Sickle Cell Patient, Clinician Patterns
An international assessment shows many patients are wary of emergency rooms, and clinicians want more diverse therapies.
The Need for Contraception Guidance in Sickle Cell Disease
Defined roles and research-informed recommendations are lacking for clinicians navigating birth control with females with sickle cell.
Why Sickle Cell Disease Clinicians Provide Different Contraceptive Guidance
New ASH 2021 data shows how guidance is still lacking for clinicians responsible for addressing contraception with women with sickle cell disease.
The State of C Difficile Care
Bincy Abraham, MD, led the State of Science program on C difficile infections.
Ulcerative Colitis Study Could Forecast Future Success of ABX464
The treatment also has potential in Crohn's disease and rheumatoid arthritis.
Aaron Baggish, MD: Making Sense of the Cardiovascular Risks of COVID-19
Several different cardiovascular symptoms have presented in patients with COVID-19.
Understanding C Difficile Infections
The State of the Science events allows experts to come together to update on recent research for CDI.
Erin D. Michos, MD, MHS: Managing Dyslipidemia with Novel Agents
A case for more proactive lipid-lowering treatment initiation in a high-risk population.
Where to Screen the Next Generation of Cardiovascular-Risk Patients
Lipid testing rates are very low among those under 40 years old. Where do clinicians best target high-risk patients—and how?
Andrew Moran, MD, MPH: The Value of Earlier Lipid Intervention
Adults 40 years and younger generally aren't tested for lipid level risk—a byproduct of national guidance and clinical trial needs.
James Mulshine, MD: Advancements in CT Screening for Lung Cancer
Dr. Mulshine and Dr. Rizzo discuss the diagnostic evolution detailed in several studies in the previous decades, and how CT screening can be used to detect lung cancer early in patients.
Theodore Leng, MD: Characterizing the Definition, Rates of Intermediate Dry AMD
Dr. Leng discusses the progression of dry AMD patients in the IRIS registry from early stages to potential GA, as well as the benefit in narrowing the clinical definition of intermediate dry AMD.
Robert L. Avery, MD Highlights Results on RGX-314 For the Treatment Of Wet AMD
Dr. Avery discusses the positive results of RGX-314 gene therapy, noting dramatic reduction in need for therapy, with stable vision and good thickness results
Dilsher S. Dhoot, MD: Efficacy of Brolucizumab in Treatment of Diabetic Macular Edema
Dr. Dhoot discusses data on visual acuity from the phase 3 KESTREL and KITE trials, comparing brolucizumab to aflibercept at 52 weeks.
Deepak Bhatt, MD, MPH: Promising Data From the REVERSE-IT Trial
There was a 135% reduction in platelet inhibition observed within 5-10 minutes following bentracimab infusion.
Rishi P. SIngh, MD: Advances and Challenges in Neovascular AMD Treatment
Dr. Singh discusses the aging population in ophthalmology care, advances including port delivery systems, and the potential rapid uptake of faricimab in treatment.
Rishi P. SIngh, MD: Durability of Faricimab in Neovascular AMD Treatment
Dr. Singh discusses results from TENAYA and LUCERNE on faricimab compared to afilbercept in patients with nAMD.
Ammara Mushtaq, MD: Understanding C Difficile Infections
There has recently been more community spread of C difficile infections.
Kazuki Yoshida, ScD: Treat-to-Target Proves Safe for Gout Therapy
New ACR findings supporting rheumatology societies' advocacy for more intensive therapy strategies, with proof of safety.
Mena Boules, MD: The Challenge in Finding a Treatment for EoE
There currently is not an approved treatment for EoE by the US Food and Drug Administration.
Marla C. Dubinsky, MD: Finding Biomarkers in IBD
Patients with the absence of urgency had significantly greater reductions in levels of inflammatory biomarkers C-reactive protein and fecal calprotectin in a cohort of patients treated with mirikizumab.
Evan S. Dellon, MD: Dupilumab for EoE at ACG 2021
ACG represents the first major in-person conference since the COVID-19 pandemic.
Paul Feuerstadt, MD: The Value of Antimicrobial Stewardship for C Difficile
Dr. Feuerstadt presented data about RBX2660 during the recent ACG 2021 meeting.
Marla C. Dubinsky, MD: Measuring Urgency in Ulcerative Colitis
An absence of urgency was associated with greater reductions in levels of inflammatory biomarkers C-reactive protein and fecal calprotectin in a cohort of patients treated with mirikizumab.
Evan S. Dellon, MD: A Daily Diary for Eosinophilic Esophagitis
PROSE allows patients to report their symptoms of dysphagia in real-time.
2 Clarke Drive Cranbury, NJ 08512